Kura Oncology Inc (KURA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $713.90M
Last updated: Nov 17, 2026 at 11:05 AM ET
Kura Oncology Inc (KURA) Earnings: Report Dates and Results
Kura Oncology (KURA) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Kura Oncology reported EPS of -$0.78, above the -$0.83 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KURA has an expected report date of Mar 3, 2027.
KURA Earnings Call
The latest KURA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, KURA beat 22, missed 12 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $22.84M, up 10.1% from $20.75M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.78 | -$0.83 | -$0.99 - -$0.70 | +6.02% | Beat | N/A | 11 | N/A | Nov 10, 2026 | $22.84M |
| Jun 30, 2026 | -$0.77 | -$0.89 | -$1.02 - -$0.72 | +13.48% | Beat | N/A | 9 | 1 up, 0 down | Aug 12, 2026 | $20.87M |
| Mar 31, 2026 | -$0.83 | -$0.90 | -$1.06 - $0.47 | +8.35% | Beat | N/A | 9 | 0 up, 3 down | May 12, 2026 | $18.27M |
| Dec 31, 2025 | -$0.92 | -$0.49 | -$0.99 - $0.11 | -87.76% | Miss | N/A | 9 | 1 up, 4 down | Mar 5, 2026 | $17.34M |
| Sep 30, 2025 | -$0.85 | -$0.68 | -$0.98 - $0.49 | -25.00% | Miss | N/A | 9 | 1 up, 6 down | Nov 4, 2025 | $20.75M |
| Jun 30, 2025 | -$0.75 | $0.15 | -$0.86 - $0.18 | -600.00% | Miss | N/A | 9 | 5 up, 2 down | Aug 7, 2025 | $15.29M |
| Mar 31, 2025 | -$0.66 | -$0.60 | -$0.84 - -$0.04 | -10.00% | Miss | N/A | 8 | 1 up, 5 down | May 1, 2025 | $14.11M |
| Dec 31, 2024 | -$0.22 | -$0.64 | -$0.75 - -$0.39 | +65.49% | Beat | N/A | 10 | 4 up, 4 down | Feb 26, 2025 | $53.88M |
| Sep 30, 2024 | -$0.63 | -$0.61 | -$0.67 - -$0.57 | -3.28% | Miss | N/A | 14 | 0 up, 0 down | Nov 7, 2024 | N/A |
| Jun 30, 2024 | -$0.59 | -$0.62 | -$0.69 - -$0.57 | +4.84% | Beat | N/A | 12 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$0.59 | -$0.54 | -$0.68 - -$0.44 | -9.26% | Miss | N/A | 11 | 0 up, 0 down | May 2, 2024 | N/A |
| Dec 31, 2023 | -$0.55 | -$0.55 | -$0.68 - -$0.49 | 0.00% | In line | N/A | 14 | 2 up, 0 down | Feb 27, 2024 | $1.27M |
| Sep 30, 2023 | -$0.50 | -$0.55 | -$0.68 - -$0.50 | +9.09% | Beat | N/A | 13 | 0 up, 0 down | Nov 2, 2023 | N/A |
| Jun 30, 2023 | -$0.53 | -$0.56 | -$0.69 - -$0.51 | +5.36% | Beat | N/A | 12 | 0 up, 0 down | Aug 3, 2023 | N/A |
| Mar 31, 2023 | -$0.50 | -$0.54 | -$0.65 - -$0.49 | +7.41% | Beat | N/A | 9 | 0 up, 0 down | May 10, 2023 | N/A |
| Dec 31, 2022 | -$0.49 | -$0.57 | -$0.65 - -$0.53 | +14.04% | Beat | N/A | 10 | 0 up, 0 down | Feb 23, 2023 | N/A |
| Sep 30, 2022 | -$0.53 | -$0.56 | -$0.66 - -$0.53 | +5.36% | Beat | N/A | 9 | 0 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$0.52 | -$0.52 | -$0.61 - -$0.49 | 0.00% | In line | N/A | 9 | 0 up, 0 down | Aug 3, 2022 | N/A |
| Mar 31, 2022 | -$0.49 | -$0.52 | -$0.53 - -$0.50 | +5.77% | Beat | N/A | 7 | 0 up, 0 down | May 4, 2022 | N/A |
| Dec 31, 2021 | -$0.49 | -$0.53 | -$0.62 - -$0.48 | +7.55% | Beat | N/A | 8 | 1 up, 0 down | Feb 24, 2022 | N/A |
| Sep 30, 2021 | -$0.50 | -$0.54 | -$0.64 - -$0.51 | +7.41% | Beat | N/A | 7 | 0 up, 0 down | Nov 4, 2021 | N/A |
| Jun 30, 2021 | -$0.51 | -$0.50 | -$0.61 - -$0.44 | -2.00% | Miss | N/A | 7 | N/A | Aug 5, 2021 | N/A |
| Mar 31, 2021 | -$0.46 | -$0.42 | -$0.46 - -$0.39 | -9.52% | Miss | N/A | 6 | N/A | May 6, 2021 | N/A |
| Dec 31, 2020 | -$0.45 | -$0.45 | -$0.61 - -$0.40 | 0.00% | In line | N/A | 10 | N/A | Feb 24, 2021 | N/A |
| Sep 30, 2020 | -$0.42 | -$0.40 | -$0.50 - -$0.30 | -5.00% | Miss | N/A | 8 | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | -$0.40 | -$0.43 | -$0.46 - -$0.32 | +6.98% | Beat | N/A | 9 | N/A | Aug 6, 2020 | N/A |
| Mar 31, 2020 | -$0.42 | -$0.42 | -$0.45 - -$0.33 | 0.00% | In line | N/A | 7 | N/A | May 4, 2020 | N/A |
| Dec 31, 2019 | -$0.39 | -$0.41 | -$0.49 - -$0.38 | +4.88% | Beat | N/A | 8 | N/A | Feb 25, 2020 | N/A |
| Sep 30, 2019 | -$0.36 | -$0.39 | -$0.44 - -$0.35 | +7.69% | Beat | N/A | 9 | N/A | Nov 5, 2019 | N/A |
| Jun 30, 2019 | -$0.38 | -$0.41 | -$0.46 - -$0.36 | +7.32% | Beat | N/A | 8 | N/A | Aug 1, 2019 | N/A |
| Mar 31, 2019 | -$0.37 | -$0.44 | -$0.46 - -$0.42 | +15.91% | Beat | N/A | 7 | N/A | May 7, 2019 | N/A |
| Dec 31, 2018 | -$0.42 | -$0.42 | -$0.46 - -$0.37 | 0.00% | In line | N/A | 8 | N/A | Mar 5, 2019 | $2.44M |
| Sep 30, 2018 | -$0.40 | -$0.43 | -$0.47 - -$0.40 | +6.98% | Beat | N/A | 7 | N/A | Nov 5, 2018 | N/A |
| Jun 30, 2018 | -$0.45 | -$0.43 | -$0.51 - -$0.34 | -4.65% | Miss | N/A | 5 | N/A | Aug 6, 2018 | N/A |
| Mar 31, 2018 | -$0.46 | -$0.35 | -$0.38 - -$0.30 | -31.43% | Miss | N/A | 6 | N/A | May 8, 2018 | N/A |
| Dec 31, 2017 | -$0.37 | -$0.36 | -$0.41 - -$0.32 | -2.78% | Miss | N/A | 6 | N/A | Mar 12, 2018 | N/A |
| Sep 30, 2017 | -$0.38 | -$0.38 | -$0.49 - -$0.29 | 0.00% | In line | N/A | 5 | N/A | Nov 7, 2017 | N/A |
| Jun 30, 2017 | -$0.40 | -$0.43 | -$0.44 - -$0.41 | +6.98% | Beat | N/A | 4 | N/A | Aug 7, 2017 | N/A |
| Mar 31, 2017 | -$0.39 | -$0.42 | -$0.50 - -$0.40 | +7.14% | Beat | N/A | 4 | N/A | May 15, 2017 | N/A |
| Dec 31, 2016 | -$0.38 | -$0.40 | N/A | +5.00% | Beat | N/A | N/A | N/A | Mar 14, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.18, after -$2.03 the year before. It was -$1.47 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.18 | N/A |
| Dec 31, 2024 | -$2.03 | N/A |
| Dec 31, 2023 | -$2.08 | N/A |
| Dec 31, 2022 | -$2.03 | N/A |
| Dec 31, 2021 | -$1.96 | N/A |
| Dec 31, 2020 | -$1.69 | N/A |
| Dec 31, 2019 | -$1.50 | N/A |
| Dec 31, 2018 | -$1.73 | N/A |
| Dec 31, 2017 | -$1.54 | N/A |
| Dec 31, 2016 | -$1.47 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,900 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,907 | 16 | |
| 2026Q2 | Jun 30, 2026 | 6,022 | 17 | |
| 2026Q1 | Mar 31, 2026 | 5,402 | 17 | |
| 2025Q4 | Dec 31, 2025 | 5,762 | 16 | |
| 2025Q3 | Sep 30, 2025 | 5,428 | 13 | |
| 2025Q2 | Jun 30, 2025 | 7,321 | 16 | |
| 2025Q1 | Mar 31, 2025 | 7,022 | 17 | |
| 2024Q4 | Dec 31, 2024 | 8,991 | 17 |
2026Q3 Earnings Call
Opening remarks
Greg Mann SVP of Investor Relations and Corporate Affairs Thank you, Ronnie. Good afternoon, everyone. Joining me today are Dr. Troy Edward Wilson, President and Chief Executive Officer; Brian T. Powl, Chief Commercial Officer; Dr. Mollie Leoni, Chief Medical Officer; and Jennifer Fulk, Chief Financial Officer. Today's discussion includes forward-looking statements based on our current expectations and management's judgment as of today. Actual results could differ materially because of risks and uncertainties, including those described in our SEC filings. Please refer to these filings, which are available through the SEC and on our website, for information concerning risk factors that could affect the company. With that, I will turn the call over to Troy.
Troy Edward Wilson President and Chief Executive Officer Thank you, Greg. Good afternoon, everyone. I am happy to report we delivered another quarter of strong growth and sustained commercial leadership. COMZIFTI net product revenue reached $13.9 million, up 53% sequentially, and new patient starts increased 30%. We maintained majority share of menin inhibitor new patient starts, reflecting continued physician preference for COMZIFTI. Our priority is to grow our leadership in this setting while building the clinical evidence to support expansion into earlier treatment settings and combinations. We are heading into ASH with an unprecedented ziftomenib presence, including four oral presentations and our first clinical data on ziftomenib combined with FLT3 inhibitors in both newly diagnosed and relapsed or refractory AML. Roughly half of patients with NPM1-mutated AML have a concurrent FLT3 mutation, and that prevalence makes FLT3 inhibitor combinations a critical part of our strategy to establish ziftomenib as a foundational AML therapy. These studies are among eight ziftomenib abstracts at ASH, and Mollie will discuss how these studies address the opportunity and inform our next development decisions. Turning to our FTI program, we are very excited to announce we have aligned with the FDA on a single-arm monotherapy registrational study with darlafarnib in HRAS-mutant salivary gland cancer. This puts our second potential precision oncology product on a focused path toward registration. This approach may deliver a new class of treatment in a molecularly defined patient population with substantial unmet need. Importantly, it could also provide a strong clinical, regulatory, and commercial foundation while we pursue larger indications in combination and through supplemental applications. We enter this next phase for Kura from a position of financial strength. Our strategic financing agreement with OrbiMed gives us flexibility to deliver key milestones for ziftomenib and darlafarnib. I am pleased to welcome Jennifer to her first call as our Chief Financial Officer. She will discuss the financing, funding outlook, and our capital allocation priorities. Finally, we established Caspian Therapeutics to advance menin inhibitors for diabetes and other chronic metabolic diseases. Kura contributed KO-7.25 thousand and related intellectual property and know-how.
Frequently Asked Questions About KURA
When is Kura Oncology's next earnings date?
Kura Oncology's next earnings report is expected for Mar 3, 2027.
Did KURA beat earnings estimates last quarter?
Yes. Kura Oncology reported EPS of -$0.78 for the quarter ended Sep 30, 2026, above the -$0.83 estimate, a 6.02% surprise.
What EPS do analysts expect from KURA next quarter?
The consensus EPS estimate for Kura Oncology for the quarter ending Dec 31, 2026 is -$0.86 from 17 analysts, with estimates from -$1.07 to -$0.72.
How often does KURA beat earnings estimates?
Kura Oncology beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -78.68%.
KURA pages: Overview, Earnings, Forecast, Financials, Competitors